{"id":"NCT03131219","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)","officialTitle":"A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-31","primaryCompletion":"2022-12-20","completion":"2022-12-20","firstPosted":"2017-04-27","resultsPosted":"2020-09-16","lastUpdate":"2024-03-15"},"enrollment":34,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atypical Hemolytic Uremic Syndrome (aHUS)"],"interventions":[{"type":"BIOLOGICAL","name":"Ravulizumab","otherNames":["ALXN1210","Ultomiris"]}],"arms":[{"label":"Ravulizumab","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to assess the efficacy of ravulizumab to control disease activity in children and adolescents with aHUS who have not previously used a complement inhibitor (complement inhibitor treatment-naïve), as well as in complement inhibitor-experienced (eculizumab-experienced) adolescent participants.","primaryOutcome":{"measure":"Percentage Of Complement Inhibitor Treatment-naïve Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26","timeFrame":"Week 26","effectByArm":[{"arm":"Complement Inhibitor Treatment Naïve","deltaMin":77.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":18,"countries":["United States","Belgium","Germany","Italy","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["32299680","39105067","33783815","33048203"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=ALXN1210-aHUS-312&amp;attachmentIdentifier=5ae2d7b1-7696-4a07-bb98-7e5aeac5849c&amp;fileName=ALXN1210-aHUS-312_EOS_Addendum_Synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":24},"commonTop":["Pyrexia","Nasopharyngitis","Vomiting","Headache","Upper respiratory tract infection"]}}